Finding a niche for each antiepileptic drug has become challenging as more new agents are approved. In this article, the most recent information regarding these drugs is reported, with emphasis on the agents approved in the past 10 years. The evidence clearly shows that, despite limited Food and Drug Administration indications, all drugs are useful in monotherapy, and many have broader spectrums of action. Adverse effects can also help distinguish between agents. Familiarity with this latest information will help clinicians make the best choice for each of their patients with epilepsy.